Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2011
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patientsIlaria Iacobucci, Anna Ferrari, Annalisa Lonetti, et al.
Plos One|August 1, 2012
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemiaIlaria Iacobucci, Nunzio Iraci, Monica Messina, et al.
International Journal of Molecular Sciences|September 28, 2024
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic TargetsSamantha Bruno, Enrica Borsi, Agnese Patuelli, et al.
Haematologica|August 10, 2012
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapySabrina Angelini, Simona Soverini, Gloria Ravegnini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2004
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
Blood|July 25, 2008
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistanceIlaria Iacobucci, Annalisa Lonetti, Francesca Messa, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2011
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patientsIlaria Iacobucci, Anna Ferrari, Annalisa Lonetti, et al.
Plos One|August 1, 2012
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemiaIlaria Iacobucci, Nunzio Iraci, Monica Messina, et al.
International Journal of Molecular Sciences|September 28, 2024
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic TargetsSamantha Bruno, Enrica Borsi, Agnese Patuelli, et al.
Haematologica|August 10, 2012
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapySabrina Angelini, Simona Soverini, Gloria Ravegnini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2004
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
Blood|July 25, 2008
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistanceIlaria Iacobucci, Annalisa Lonetti, Francesca Messa, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Pageof 17